CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.

Earnings have fallen but are still strong enough to meet CVS Health's dividend commitment. Management expects adjusted ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

CVS Pharmacy thinks it has found a solution to customer complaints about locked display cases - but the cure may be worse ...

CVS’s stock soared toward after its quarterly profit beat expectations by the widest margin in more than four years.

CVS Health (CVS) stock soared about 15% yesterday after posting upbeat fourth-quarter results, with revenues and earnings ...

CVS Health (NYSE:CVS – Free Report) had its price target lifted by JPMorgan Chase & Co. from $80.00 to $81.00 in a report ...

Some analysts are more optimistic about CVS’ ability to navigate higher-than-expected medical costs in its insurance unit ...

Principal Securities Inc. grew its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 3.2% during the fourth ...

We recently compiled a list of the 10 Best Performing S&P 500 Stocks So Far in 2025. In this article, we are going to take a ...

The S&P 500 dropped 0.3% on Wednesday, Feb. 12, as hotter-than-expected inflation data in the January CPI report weighed on ...

CVS Health exceeded Q4 sales estimates with $97.71B revenue. The company projects 2025 revenue above $134B and expects ...